Real-World Outcomes of Iptacopan in C3 Glomerulopathy and Primary Immune Complex–Mediated Membranoproliferative Glomerulonephritis Authors: Giulia Bassanese, Ariel Martje Weingarten, Maddalena Marasà, Maria Cristina Mancuso, Luis F Quintana Porras, Soumita Bagchi, Federico Alberici, Olivia Boyer, Luigi Cirillo, Michaela Geßner, Domenico Giannese, Günter Klaus, Jerome Harambat, Raquel López Hidalgo, Patricia Hirt-Minkowski, Ana Huerta, Arenn Jauhal, Sebastian Loos, Sigrid Lundberg, Federica Maritati, Annick Massart, Aude Servais, Renato Alberto Sinico, Jutta Schröder-Braunstein, Marina Vivarelli, Franz Schaefer, The CompCure Consortium Published: 2026 Introduction C3 glomerulopathy (C3G) and primary immune complex-membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases driven by complement dysregulation.1,2 Current treatment relies on supportive care and nonspecific immunosuppression,2 highlighting the need for targeted approaches such as proximal complement inhibition.3 Iptacopan, an oral and selective inhibitor of factor B, has demonstrated efficacy and safety in phase 2 and randomized phase 3 clinical studies in adults with C3G,3, 4, 5 leading to regulatory approval.6 We report real-world outcomes of iptacopan in patients ineligible for clinical trials or treated outside formal study programs. A full protocol is provided in the Supplementary Methods. Results Patient Characteristics Patient were identified through the ERKNet CompCure Registry7 and an international survey of non-ERKNet centers. On diagnosis, the median urinary protein-to-creatinine ratio (uPCR) was 4.2 [interquartile range, 2.92–5.20] g/g and the mean estimated glomerular filtration rate (eGFR) was 81.1 (35.6) ml/min per 1.73 m2. Patients with IC-MPGN were older at onset than those with C3G (median age, 34.5 [19.0–48.3] vs. 17.9 [14.8–22.8] years) and had numerically lower uPCR (3.48 [2.44–4.42] vs. 4.40 [3.14–5.24] g/g) and eGFR (59 [29] vs. 76 [39] ml/min per 1.73 m2). Treatment History and Disease Activity Before Iptacopan Administration All but 2 patients received renin-angiotensin system inhibitors (Table 1). Before iptacopan, 25% received intravenous steroid pulses, 64% received oral prednisone, 86% received mycophenolate mofetil, and 18% received a calcineurin inhibitor. After these treatments, proteinuria transiently improved (nadir uPCR of 1.31 [0.60–2.75] g/g) before relapsing. Transient complete remission according to the predefined age-specific thresholds (Supplementary Methods) occurred in 3 C3 glomerulonephritis patients. At initiation of iptacopan therapy, median uPCR was 3.50 [1.55–6.20] g/g. Table 1Baseline demographic, clinical, laboratory, histopathological, and treatment characteristics of the study cohort overall and stratified by response status (responders vs. nonresponders), including variables at diagnosis and at initiation of iptacopan treatmentTotal cohort (n = 28)Responders (n = 21)Nonresponders (n = 7)P-valueBaseline characteristicsDiagnosisC3GN22 (79%)18 (85.7%)4 (57.1%)0.86DDD2 (7%)1 (4.8%)1 (14.3%)IC-MPGN4 (14%)2 (9.5%)2 (28.6%)Female sex, n (%)18 (64%)14 (66.7%)4 (57.1%)0.9EthnicityCaucasian25 (89.3%)19 (90.5%)60.9Indian2 (7.1%)2 (9.5%)(85.7%)African1 (3.6%)0 (0%)1 (14.3%)HistopathologyMembranoproliferative GN24 (85.7%)18 (85.7%)6 (85.7%)1Mesangioproliferative GN4 (14.3%)3 (14.3%)1 (14.3%)Crescentic GN0 (0%)0 (0%)0 (0%)Immunofluorescence: C3 dominant24/24 (100%)19/19 (100%)5/5 (100%)1Characteristics at time of diagnosisAge, yr18.9 (14.5–26.5)22.0 (16.0–47.0)15.0 (13.5–15.8)0.49Age < 18 yrs, n (%)13 (46%)7 (33.3%)6 (85.7%)0.53ImmunomarkersLow serum C3, n (%)25 (89.3%)19 (90.5%)6 (85.7%)0.9Elevated sC5b9, n (%)10/10 (100%)3/3 (100%)7/7 (100%)1.0C3 nephritic factor positive5/16 (31%)5/11 (45.5%)0/5 (0%)0.73eGFR, ml/min per 1.73 m281.1 (35.6)79.7 (34.4)85.1 (41.5)0.88uPCR, g/g4.2 (2.9–5.2)4.3 (2.7–5.2)3.8 (3.0–5.2)1Medications before IptacopanRAS blockade26 (92.9%)19 (90.5%)7 (100%)1Intravenous methylprednisolone pulses7 (25.0%)6 (28.6%)1 (14.3%)1Oral prednisone18 (64.3%)12 (57.1%)6 (85.7%)0.36Mycophenolate mofetil24 (85.7%)18 (85.7%)6 (85.7%)1Calcineurin inhibitor5 (17.9%)3 (14.3%)2 (28.6%)0.57Characteristics at start of iptacopanAge, yrs22.9 (18.8–28.3)23.4 (19.7–52.5)18.0 (15.5–22.3)0.048Age < 18 r, n (%)6 (21.4%)3 (14.3%)3 (42.9%)0.71Disease duration, yrs3.1 (1.9–5.1)3.1 (1.4–5.0)3.4 (2.3–4.8)0.88Low serum C3, n (%)26 (92%)20 (95.2%)6 (85.7%)eGFR, ml/min per 1.73 m272.3 (38.3)71.1 (39.6)76.8 (36.5)0.98uPCR, g/g3.5 (1.6–6.2)3.7 (2.2–6.8)1.8 (1.2–4.2)0.28uPCR ≤ 1 g/g5/28 (17.8%)4/21 (19%)1/7 (14%)Comedications at start of IptacopanRAS blockade24 (85.7%)18 (85.7%)6 (85.7%)1Oral prednisone5 (17.9%)3 (14.3%)2 (28.6%)0.57Mycophenolate mofetil13 (46.4%)8 (38.1%)5 (71.4%)0.20Calcineurin inhibitor0 (0%)0 (0%)0 (0%)1Normal serum C3 at 3 mos, n (%)20/27 (74%)15/21 (71.4%)5/6 (83.3%)1ACR, acute cellular rejection; C3G, C3 glomerulopathy; C3GN, C3 glomerulonephritis; DDD, dense deposit disease; GN, glomerulonephritis; IC-MPGN, immune complex–mediated membranoproliferative glomerulonephritis; IQR, interquartile range; SD, standard deviation; RAS, renin-angiotensin system; uPCR, urinary protein-to-creatinine ratio; yr, years(s).Continuous variables are presented as mean (SD) or median [IQR], as appropriate, and categorical variables as n (%). Responders were defined as patients achieving a ≥ 15% reduction in uPCR from baseline at 6 months without a persistent decline in eGFR. In this study, "sex" refers to biological sex as recorded in the patients' medical records and entered into the registry. Baseline demographic, clinical, laboratory, histopathological, and treatment characteristics of the study cohort overall and stratified by response status (responders vs. nonresponders), including variables at diagnosis and at initiation of iptacopan treatment ACR, acute cellular rejection; C3G, C3 glomerulopathy; C3GN, C3 glomerulonephritis; DDD, dense deposit disease; GN, glomerulonephritis; IC-MPGN, immune complex–mediated membranoproliferative glomerulonephritis; IQR, interquartile range; SD, standard deviation; RAS, renin-angiotensin system; uPCR, urinary protein-to-creatinine ratio; yr, years(s). Continuous variables are presented as mean (SD) or median [IQR], as appropriate, and categorical variables as n (%). Responders were defined as patients achieving a ≥ 15% reduction in uPCR from baseline at 6 months without a persistent decline in eGFR. In this study, "sex" refers to biological sex as recorded in the patients' medical records and entered into the registry. Mean eGFR temporarily increased from 81 (36) to 100 (41) ml/min per 1.73 m2 but subsequently decreased again to 72 (38) ml/min per 1.73 m2 before iptacopan administration, including 7 (of whom 2 IC-MPGN) patients with eGFR < 30 ml/min per 1.73 m2 (Table 1). Iptacopan Treatment Efficacy At initiation of iptacopan, median uPCR was 3.50 [1.6–6.2] g/g, mean eGFR had declined to 72.3 (38.3) ml/min per 1.73 m2 (with 7 patients < 30 ml/min per 1.73 m2), and serum C3 levels remained low in 26 of 28 patients. The treatment was started at a median [interquartile range] time of 3.1 [1.9–5.1] years after diagnosis and was administered for a mean duration of 15.8 (10.6) months. Overall, 6 patients were managed in pediatric nephrology units, including 4 with C3 glomerulonephritis, 1 with dense deposit disease, and 1 with IC-MPGN. Most patients continued background renin-angiotensin system inhibitors, whereas a subset remained on mycophenolate mofetil or low-dose corticosteroids (Table 1). Linear mixed-effects modeling demonstrated reduction in mean uPCR of 36 (31–41) % (P = 0.0057), 52 (43–60) % (P = 0.0029), 56 (54–58) % (P = 0.0038), and 48 (39–63) % (P = 0.016) at 1, 3, 6, and 12 months, respectively (Figure 1 and Supplementary Figure S2). In the pediatric subgroup (n = 6; [median age, 15.2 years]), iptacopan treatment led to a reduction in median uPCR from 3.5 g/g at baseline to 1.9 g/g at 12 months, with stable kidney function. No baseline characteristics or concomitant therapies significantly influenced uPCR trajectories. Changes in serum C3, uPCR, and kidney function during iptacopan treatment. (a) Serum C3 concentrations, (b) uPCR, and (c) eGFR are shown at baseline and after 1, 3, 6, and 12 months of treatment. Serum C3 and eGFR are presented as mean ± SEM, whereas uPCR is presented as geometric mean with 95% CI. Numbers within the bars indicate the number of patients with available measurements at each time point. CI, confidence interval; eGFR, estimated glomerular filtration rate; SEM, standard error of the mean; uPCR, urinary protein-to-creatinine ratio. Among 23 patients with uPCR > 1 g/g at baseline, 2 patients(1 IC-MPGN and 1 C3G) achieved complete and 8 patients (1 IC-MPGN) achieved partial proteinuria remission. Complete remission was also observed in 3 out of 5 patients with baseline uPCR ≤ 1 g/g. Proteinuria was reduced to < 1 g/g in 6 of the 20 patients (30%) exceeding this threshold at baseline who had available data at 6 months (Supplementary Figure S3). Kidney function remained stable throughout the follow-up. Mean eGFR values at baseline and after 12 months of treatment were similar (73 ± 36 ml/min per 1.73 m2), and no overall decline in eGFR was observed during iptacopan exposure. Of note, 1 patient experienced a marked and sustained improvement in eGFR from 30 to 59 ml/min per 1.73 m2 (Supplementary Figure S3). Serum C3 increased rapidly after the treatment initiation and normalized in 74% of patients by month 3 (Table 1 and Figure 1). Characteristics of Nonresponders Despite the overall favorable response, 7 patients (25%) exhibited no reduction or an increase in proteinuria at 6 months, leading to treatment discontinuation in 2 cases. Of note 2 nonresponders showed an initial reduction in proteinuria followed by subsequent rebound (Supplementary Figure S3). Compared with the responders (Table 1), nonresponders were significantly younger; however, disease duration, baseline proteinuria, eGFR, and complement levels, and C3 nephritic factor positivity (available in a limited number of patients) did not differ significantly. Repeat Kidney Biopsy Results Paired kidney biopsies in 2 patients with C3G (1 responder and 1 nonresponder) showed resolution of endocapillary inflammatory activity and attenuation of the membranoproliferative pattern, with minimal chronic damage. In the nonresponder, C3 deposits persisted despite histologic improvement. Electron microscopy was not performed in either case (Supplementary Results). Adverse Events Iptacopan was well tolerated and during a cumulative exposure of 293 treatment-months, 2 mild adverse events were reported: 1 asymptomatic, reversible elevation of pancreatic enzymes and 1 episode of sinusitis. No serious adverse events requiring hospitalization, treatment discontinuation, or infections with encapsulated bacteria were reported. Discussion This real-world data analysis extends evidence from the APPEAR clinical trial program3, 4, 5 by demonstrating the efficacy and safety of iptacopan in a broader cohort of patients with primary C3G and IC-MPGN, including two-thirds of the patients who would not have met previous trial eligibility criteria. Iptacopan treatment was associated with a 56% mean reduction in uPCR at 6 months, with a numerically higher proportion of patients achieving uPCR < 1 g/g (30%) or partial remission (40%) than reported in the APPEAR-C3G trial data.5 The numerical difference between the 6-month (56%) and 12-month (48%) uPCR reduction may reflect the increased data variability and the smaller number of patients with complete 1-year follow-up typical of a real-world cohort, rather than a loss of clinical efficacy. Kidney function remained stable, consistent with the findings from the APPEAR-C3G trial program.3, 4, 5 Serum C3 normalized in most patients by month 3; however, it remained low in 7 of 27 patients and normalization was not associated with clinical response, possibly reflecting incomplete target inhibition or individual pharmacokinetic variability. Iptacopan was generally well tolerated; adverse events were actively ascertained, although minor events may be less consistently captured than in prospective trials. Despite the overall reduction in proteinuria in this clinically complex population, in whom conventional immunosuppression had often failed to provide sustained disease control, responses varied widely, from complete remission to nonresponse. This variability underscores the need for better molecular characterization and biomarker-based patient stratification. Despite the limited sample size, this is the largest real-world cohort reported to date and supports the use of targeted alternative pathway inhibition in routine clinical practice. Appendix The CompCure Consortium collaborators Klaus Arbeiter, Christoph Aigner, Evelien Snauwaert, Brigitte Adams, Katheleen Claes, Lovro Lamot, Jakub Zieg, Łukasz Obrycki, Tereza Metelcová, Søren Rittig, René Andersen, Ida Maria Schmidt, Bruno Ranchin, Olivia Gillion-Boyer, Aude Servais, Jérôme Harambat, Yahsou Delmas, Stéphane Decramer, Denis Morin, Evelyn Seelow, Philipp Krohmann, Juliane Beckus, Lars Pape, Ludwig Patzer, Jun Oh, Sebastian Loos, Franz Schaefer, Joanna Sladowska-Kozlowska, Giulia Bassanese, Nele Kanzelmeyer, Dieter Haffner, Vega Goedecke, Martin Konrad, Kathrin Buder, Diletta Domenica Torres, Marta Lepore, Andrea Pasini, Federico Alberici, Luigi Cirillo, Francesca Lugani, Antonio Mastrangelo, Maria Cristina Mancuso, Rita Santarsiere, Enrico Vidal, Nicola Bertazzi Partigiani, Marina Vivarelli, Roberta Fenoglio, Giulio Del Vecchio, Danilo Radunović, Elena Levtchenko, Antonia Bouts, Y.K. Onno Teng, Koen de Koning, Nicole van de Kar, Anne Eis van de Logt, Valentina Gracchi, Beata Bienias, Magdalena Drozynska-Duklas, Dorota Drozdz, Małgorzata Stańczyk, Katarzyna Kiliś-Pstrusińska, Alberto Caldas Afonso, Anna Teixeira, Anca Marin, Dusan Paripovic, Gordana Miloševski-Lomić, Tanja Kersnik Levart, Andreja Aleš Rigler, Gema Ariceta, Carla Soto, Luis Quintana, Mar Espino Hernández, Enrique Morales, Aysun Karabay Bayazit, Bahriye Atmis, Nur Canpolat, Alev Yilmaz, Ipek Kaplan Bulut, Hong Xu, Qian Shen, Chunyan Wang, Shirley Pollack, Larisa Prikhodina, Hee Gyung Kang, Ingyeong Lee. Disclosure FA reports research support from Sanofi and honoraria for lectures and consultancy from CSL Vifor, Alexion, and Amicus Therapeutics. GB reports research grants to the institution from the CompCure Association, Novartis, and SOBI. OB reports consultancy fees and sponsored lectures from Advicenne, Alexion, Alnylam, Biocodex, Chiesi, CSL Vifor, Novartis, Samsung, Sobi, and Takeda. SB is a site investigator in clinical trials for Novartis, Vera Therapeutics, and Fourrts; all funding is received directly by the institute with no personal financial interests. DG reports consultancy fees from GSK and sponsored lectures for AstraZeneca, Alexion, Vifor, and Boehringer Ingelheim. JH reports no disclosures specific to this study but consultancy fees from Alnylam, Alexion, and Bayer, and teaching honoraria from Sanofi France. PH-M reports grant from the Gottfried and Julia Bangerter-Rhyner Foundation, Amgen, CSL Vifor, and Fresenius Medical Care, as well as speaker fees from Alexion, CSL Vifor, and Novartis, and consultancy honoraria from Alexion, Novartis, and Swedish Orphan Biovitrum. AJ reports consultancy fees and honoraria from Alexion, Sobi, Novartis, Roche, Otsuka, and GSK, and clinical trial support from Alexion, Pfizer, Alnylam, and Novartis. SL reports consultancy fees from Novartis, CSL Vifor, STADA, Chinook, Sobi, and Boehringer Ingelheim; has delivered sponsored lectures for AstraZeneca; and participates as a local principal investigator in clinical trials sponsored by Calliditas, Novartis, AstraZeneca, and Vertex. MCM reports consultancy fees from SOBI, travel fees from Novartis, and speaker fees from Alexion. MM reports travel support from Novartis and participates as a site investigator in clinical trials sponsored by Apellis, Alexion, Vera Therapeutics, Biogen, and Boehringer Ingelheim. FM is involved as a coinvestigator in clinical trials sponsored by Alexion, Dimerix, and Vera Therapeutics. AM reports consultancy fees from Novartis, Apellis, and Alexion; all funding is received directly by the institute with no personal financial interests. LFQP reports consultancy fees from Novartis, GSK, Otsuka, Alexion, Roche, and CSL Vifor, and has delivered sponsored lectures for Novartis, GSK, Otsuka, Alexion, and Roche. JS-B reports consultancy fees from Novartis. AS reports consultancy fees from Novartis and Sobi and participates as a local principal investigator in clinical trials sponsored by Novartis and Alexion. FS reports research grants from Novartis and SOBI, consultancy fees, honoraria from SOBI and Novartis, and participation on a data safety monitoring board for SOBI. RS reports consultancy fees from Roche, GSK, Vifor, and Otsuka. MV has received consultancy fees from Novartis, Sobi, Apellis, Alexion, Santhera, Takeda, Vertex, and PureSpring; has delivered sponsored lectures for Roche, Novartis, Sobi, Travere, and Glaxo; and participates as a local principal investigator in clinical trials sponsored by Alexion, Apellis, Novartis, Roche, Bayer, and Travere. The remaining authors have no disclosures to report. Acknowledgments The study was supported by the CompCure Association, a nonprofit patient organization, and the European Reference Network for Rare Kidney Diseases (ERKNet). ERKNet is funded by the European Union within the framework of the EU4Health Program (101085068). We thank Novartis Pharmaceuticals, particularly Serge Smeets, for their logistical support in facilitating initial contact with treatment centers outside the ERKNet network. The company was not involved in the design, conduct, or analysis of this study. Data Availability Statement Individual-level patient data derived from the ERKNet CompCure Registry and anonymized surveys are not publicly available due to ethical and data protection constraints but may be made available upon reasonable request to the corresponding author, subject to appropriate approvals. Declaration of AI and AI-assisted Technologies in the Writing Process During the preparation of this work the authors used OpenAI in order to assist with editing and improve the clarity and readability of the manuscript. The authors reviewed and edited the content as needed and take fully responsibility for the content of the publication. Footnotes Supplementary File (PDF) Supplementary Methods. Supplementary Results. Supplementary References. Figure S1. Patient inclusion and follow-up data availability after iptacopan initiation. Figure S2. Individual percentage change in uPCR from baseline during iptacopan treatment. Figure S3. Individual longitudinal trajectories of proteinuria and kidney function following iptacopan initiation in responders and nonresponders. Contributor Information Marina Vivarelli, Email: marina.vivarelli@opbg.net. The CompCure Consortium: Klaus Arbeiter, Christoph Aigner, Evelien Snauwaert, Brigitte Adams, Katheleen Claes, Lovro Lamot, Jakub Zieg, Łukasz Obrycki, Tereza Metelcová, Søren Rittig, René Andersen, Ida Maria Schmidt, Bruno Ranchin, Olivia Gillion-Boyer, Aude Servais, Jérôme Harambat, Yahsou Delmas, Stéphane Decramer, Denis Morin, Evelyn Seelow, Philipp Krohmann, Juliane Beckus, Lars Pape, Ludwig Patzer, Jun Oh, Sebastian Loos, Franz Schaefer, Joanna Sladowska-Kozlowska, Giulia Bassanese, Nele Kanzelmeyer, Dieter Haffner, Vega Goedecke, Martin Konrad, Kathrin Buder, Diletta Domenica Torres, Marta Lepore, Andrea Pasini, Federico Alberici, Luigi Cirillo, Francesca Lugani, Antonio Mastrangelo, Maria Cristina Mancuso, Rita Santarsiere, Enrico Vidal, Nicola Bertazzi Partigiani, Marina Vivarelli, Roberta Fenoglio, Giulio Del Vecchio, Danilo Radunović, Elena Levtchenko, Antonia Bouts, Y.K. Onno Teng, Koen de Koning, Nicole van de Kar, Anne Eis van de Logt, Valentina Gracchi, Beata Bienias, Magdalena Drozynska-Duklas, Dorota Drozdz, Małgorzata Stańczyk, Katarzyna Kiliś-Pstrusińska, Alberto Caldas Afonso, Anna Teixeira, Anca Marin, Dusan Paripovic, Gordana Miloševski-Lomić, Tanja Kersnik Levart, Andreja Aleš Rigler, Gema Ariceta, Carla Soto, Luis Quintana, Mar Espino Hernández, Enrique Morales, Aysun Karabay Bayazit, Bahriye Atmis, Nur Canpolat, Alev Yilmaz, Ipek Kaplan Bulut, Hong Xu, Qian Shen, Chunyan Wang, Shirley Pollack, Larisa Prikhodina, Hee Gyung Kang, and Ingyeong Lee Supplementary Material Supplementary File (PDF) Supplementary Methods. Supplementary Results. Supplementary References. Figure S1. Patient inclusion and follow-up data availability after iptacopan initiation. Figure S2. Individual percentage change in uPCR from baseline during iptacopan treatment. Figure S3. Individual longitudinal trajectories of proteinuria and kidney function following iptacopan initiation in responders and nonresponders. References Associated Data Supplementary Materials Supplementary File (PDF) Supplementary Methods. Supplementary Results. Supplementary References. Figure S1. Patient inclusion and follow-up data availability after iptacopan initiation. Figure S2. Individual percentage change in uPCR from baseline during iptacopan treatment. Figure S3. Individual longitudinal trajectories of proteinuria and kidney function following iptacopan initiation in responders and nonresponders. Data Availability Statement Individual-level patient data derived from the ERKNet CompCure Registry and anonymized surveys are not publicly available due to ethical and data protection constraints but may be made available upon reasonable request to the corresponding author, subject to appropriate approvals. Declaration of AI and AI-assisted Technologies in the Writing Process During the preparation of this work the authors used OpenAI in order to assist with editing and improve the clarity and readability of the manuscript. The authors reviewed and edited the content as needed and take fully responsibility for the content of the publication.